Molecular insights into psychedelic drug action
- PMID: 34797943
- DOI: 10.1111/jnc.15540
Molecular insights into psychedelic drug action
Abstract
A confluence of factors has renewed interest in the scientific understanding and translational potential of psychedelic drugs such as lysergic acid diethylamide (LSD), mescaline, and psilocybin: the desire for additional approaches to mental health care, incremental progress in basic and clinical research, and the reconsideration and relaxation of existing drug policies. With the United States Food and Drug Administration's designation of psilocybin as a "Breakthrough Therapy" for treatment-resistant depression, a new path has been forged for the conveyance of psychedelics to the clinic. Essential to the further development of such applications, however, is a clearer understanding of how these drugs exert their effects at the molecular level. Here we review the current knowledge regarding the molecular details of psychedelic drug actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic mechanisms.
Keywords: G protein-coupled receptors (GPCR); neurons; psychedelics; serotonin; special issue.
© 2021 International Society for Neurochemistry.
References
REFERENCES
-
- Abbas, A., Yadav, P., Yao, W., Arbuckle, M., Grant, S., Caron, M., & Roth, B. (2009). PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. Journal of Neuroscience, 29, 7124-7136. https://doi.org/10.1523/JNEUROSCI.1090-09.2009
-
- Abramson, H. A. (1967). The use of LSD in psychotherapy and alcoholism. The Bobbs-Merrill Company.
-
- Aghajanian, G. K., & Marek, G. J. (1997). Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology, 36, 589-599. https://doi.org/10.1016/S0028-3908(97)00051-8
-
- Allen, J. A., Yadav, P. N., Setola, V., Farrell, M., & Roth, B. L. (2011). Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivo. Translational Psychiatry, 1, e33. https://doi.org/10.1038/tp.2011.35
-
- Allen, J. A., Yost, J. M., Setola, V. et al (2011). Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proceedings of the National Academy of Sciences of the United States of America, 108, 18488-18493.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
